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(ACKGROUND The diagnosis of arrhythmogenic right ventricular
ardiomyopathy can be challenging. Disease-causing mutations in
esmosomal genes have been identified. A novel diagnostic fea-
ure, loss of immunoreactivity for plakoglobin from the interca-
ated disks, recently was proposed.
BJECTIVE The purpose of this study was to identify two novel
utations in the intracellular cadherin segment of desmoglein-2
G812S and C813R in exon 15). Co-segregation of the G812S
utation with disease expression was established in a large Cau-
asian family. Endomyocardial biopsies of two individuals showed
educed plakoglobin signal at the intercalated disk.
ETHODS To understand the pathologic changes occurring in
he diseased myocardium, functional studies on three muta-
ions in exon 15 of desmoglein-2 (G812C, G812S, C813R) were
erformed.
ESULTS Localization studies failed to detect any differences in
argeting or stability of the mutant proteins, suggesting that they
ct via a dominant negative mechanism. Binding assays were
erformed to probe for altered binding affinities toward otherl
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sardiov.ox.ac.uk. (Received May 17, 2010; accepted August 9, 2010.)
547-5271/$ -see front matter © 2010 Published by Elsevier Inc. on behalf of Hhough no differences were observed for the mutated proteins in
omparison to wild-type desmoglein-2, binding to plakophilin-2
epended on the expression system (i.e., bacterial vs mammalian
rotein expression). In addition, abnormal migration of the C813R
utant protein was observed in gel electrophoresis.
ONCLUSION Loss of plakoglobin immunoreactivity from the in-
ercalated disks appears to be the endpoint of complex pathologic
hanges, and our functional data suggest that yet unknown post-
ranslational modifications of desmoglein-2 might be involved.
EYWORDS Arrhythmogenic right ventricular cardiomyopathy;
esmoglein-2; Desmosome; Genetics; Missense mutation; Plako-
hilin-2
BBREVIATIONS ARVC  arrhythmogenic right ventricular cardio-
yopathy; Cx43 connexin43; DSC2 desmocollin-2; DSG2
esmoglein-2; DSP desmoplakin; GFP green fluorescent protein;
ST glutathione-S-transferase; ICS intracellular cadherin segment;
G plakoglobin; PKP2 plakophilin-2; RV right ventricle
Heart Rhythm 2010;7:1446–1453) © 2010 Published by Elsevier Inc. on
esmosomal proteins, such as plakoglobin and plakophilin-2. Al- behalf of Heart Rhythm Society.ntroduction
rrhythmogenic right ventricular cardiomyopathy (ARVC)
s a disease of the heart muscle. It is characterized by
This work was supported by British Heart Foundation Programme
rant RG/04/010 to Drs. Gehmlich, Syrris, and McKenna; by the Heart
hythm Society to Dr. Asimaki; and by National Institutes of Health Grant
L102361 to Dr. Saffitz. Part of this work was undertaken at University
ollege London/Hospital, which received a proportion of funding from the
epartment of Health’s National Institute for Health Research Biomedical
esearch Centre. Address reprint requests and correspondence: Dr.
atja Gehmlich, Department of Cardiovascular Medicine, University of
xford, Level 6, West Wing, John Radcliffe Hospital, Headley Way,
xford OX3 9DU, United Kingdom. E-mail address: katja.gehmlich@ife-threatening arrhythmias and heart failure of predomi-
antly right ventricular (RV) origin.1 Several factors, in-
luding marked phenotypic variation, incomplete and low
30%) penetrance, and age-related disease development and
rogression contribute to the complexity of clinical diagno-
is.2 Familial disease occurs in approximately 50% of cases,
nd five genes coding for cardiac desmosomal proteins are
ssociated with the disease.3
It is widely accepted that changes in cellular adhesion
nderlie ARVC pathogenesis.3 The redistribution of plako-
lobin (PG) from junctional to intracellular pools (mirrored
y significant reduction in the amount of immunoreactive
ignal at cardiac intercalated disks) has been reported in
eart Rhythm Society. doi:10.1016/j.hrthm.2010.08.007
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1447Gehmlich et al Novel Desmoglein-2 Missense Mutations in ARVCirtually all patients with ARVC irrespective of the under-
ying pathogenic mutation.4 The mechanisms responsible
or this consistent immunohistochemical feature are cur-
ently being investigated. Preliminary data have shown that
G redistribution may be related to signal transduction
athways that appear to be pathologically activated.5
Impaired desmosomal structure and function also affect
ther cell-to-cell contact structures in the myocardium. In
articular, gap junction remodeling is often observed in
RVC patients, and these potential electrical conduction
bnormalities may favor arrhythmic events that characterize
he disease and predispose patients to high risk of sudden
ardiac death.6,7
Desmoglein-2 (DSG2) and desmocollin-2 (DSC2) are
he cardiac desmosomal cadherins, which mediate adhesion
cross cardiomyocytes via their extracellular domains.8
heir cytoplasmic portions have a conserved domain, the
ntracellular cadherin segment (ICS). This 60-amino-acid-
ong module provides the link to the intracellular desmo-
omal components PG and plakophilin-2 (PKP2), which in
urn bind desmoplakin (DSP) and thereby provide a link to
he desmin filaments.9
Approximately 10% of patients with ARVC have muta-
ions in DSG2. In the intracellular cytoplasmic portion only
wo mutations (DSG2 G812C and DSG2 V920G) have been
escribed; however, the latter is also found in 0.8% of the
ealthy population, making a causative role in ARVC
oubtful.10
Here we present two novel missense mutations in the
SG2 gene, residing in the immediate region of the previ-
usly identified G812C mutation.11 Co-segregation with the
isease phenotype could be established in the case of one
utation. Immunohistochemical analysis and functional in
itro studies are supportive of a causal role for the mutated
SG2 ICS domain in ARVC. Furthermore our data point
oward complex mechanisms underlying disease pathogen-
sis.
ethods
linical evaluation and genetic screening
he study was performed in accordance with the 1964
eclaration of Helsinki, and the study protocol was ap-
roved by the local ethics committees. All subjects pro-
ided informed consent. Clinical evaluation and genetic
creening of DSP, PG, PKP2, DSG2, DSC2, and con-
exin43 (Cx43) by direct sequencing were performed as
escribed previously.12 The diagnosis of ARVC was based
n the recent revision of the original criteria proposed by the
nternational Task Force of the European Society of Cardi-
logy and International Society and Federation of Cardiol-
gy.13
nalysis of endomyocardial biopsies
V biopsy samples obtained from the proband (A.1) and his
ister (A.3) during a right heart catheterization were histo-
ogically analyzed or immunostained as previously de-
cribed.14 dunctional studies
or localization and expression studies, full-length human
SG2 constructs fused to green fluorescent protein (GFP)
ere expressed in neonatal rat cardiomyocytes using
EGFP-N1 vector (Clontech, Takara Bio Europe, Saint-
ermain-en-Laye, France). For binding assays, DSG2 ICS
equences (amino acids 635–842 of human DSG2) were
sed in glutathione-S-transferase (GST) pulldown assays.
ull experimental details are available in the online supple-
entary material.
esults
dentification of novel DSG2 missense mutations
n families with ARVC
he index patient of a Caucasian family (individual A.1 of
amily I, Figure 1A) presented with palpitations at age 37
ears. Clinical evaluation identified 35,000 ventricular ec-
opic beats on 24-hour ECG monitoring and structural ab-
ormalities of the RV on echocardiogram. Endomyocardial
iopsy was performed targeting RV low-voltage areas iden-
ified by electroanatomic mapping.15 Histologic analysis of
he myocardial sample showed clear evidence of interstitial
nd replacement fibrosis (Online Supplement Figure 1). The
iagnosis of ARVC was made on the basis of two major and
ne minor criteria according to the revised task force criteria
Table 1).13
Genetic screening of the five cardiac desmosomal genes
nd Cx43 showed no abnormalities in DSP, PKP2, DSC2,
G, or Cx43. In DSG2, a heterozygous G¡A change was
ound in exon 15 at position c.2434, coding for a glycine to
erine amino acid change at position 812 (DSG2 G812S;
igure 1C).
The father of the index patient had died suddenly at age
2 years and had experienced palpitations and presyncope
n the past. Clinical evaluation of the family showed that the
ndex patient’s sister (individual A.3) also fulfilled diagnos-
ic criteria for ARVC (three major and one minor criteria;
able 1) in the presence of the DSG2 G812S mutation
severe dilation and reduction of RV ejection fraction on
chocardiogram, with RV outflow tract parasternal short-
xis measurement of 38 mm; 700 ventricular ectopic beats
n 24-hour ECG monitoring; fibrofatty replacement on en-
omyocardial biopsy). The brothers of the index patient
individuals A.2 and A.10) had normal ECGs and normal
chocardiography findings. They were negative for the mu-
ation, and the same applied to all of their children available
or clinical testing (individuals A.6 and A.9). The children
f both affected individuals were also investigated. Two of
hem (individuals A.5 and A.7) were found to carry the
utation and were diagnosed with ARVC (based on two
ajor criteria, akinesia of the RV apex with RV outflow
ract parasternal short-axis measurement of 36 mm; Table
). The daughter of the index patient (individual A.4) was
egative for the mutation and was clinically normal accord-
ng to ECG and echocardiographic investigation. Individual
.8 was negative for the mutation; however, his echocar-
iogram showed RV apical hypokinesia; therefore, he is
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1448 Heart Rhythm, Vol 7, No 10, October 2010lso classified as borderline for ARVC (one major and one
inor criteria; Table 1).
In a second Caucasian family, the index patient (individ-
al B.1, Figure 1B) presented with symptomatic sustained
igure 1 Identification of novel mutations in DSG2 exon 15. A: Pedigre
ndividuals fulfilling diagnostic criteria for arrhythmogenic right ventricula
ask force criteria; gray symbol indicates borderline ARVC diagnosis; blac
ndicate deceased individuals; squares indicate males; circles indicate fe
espectively; arrow indicates index patient. n.d.  individual not availab
edigree of family B with a heterozygous DSG2 C813R mutation. Symbol
osition c. 2434 (open arrow in individual A.1) compared to a normal wild
t nucleotide position c. 2437 (open arrow in individual B.1) compared to
able 1 Clinical data of arrhythmogenic right ventricular cardio
evised task force criteria13
atient Sex Age (years) Events Genotype FH/
.1 M 46 palpitations DSG2 G812S 0
.2 M 58 none WT 1M
.3 F 43 palpitations DSG2 G812S 1M
.4 F 17 WT 1M
.5 M 15 none DSG2 G812S 1M
.6 F 35 WT 0
.7 F 13 none DSG2 G812S 1M
.8 M 15 WT 1M
.9 M 30 WT 0
.10 M 56 WT 1M
.1 M 76 presyncope DSG2 C813R 0
.2 M 57 none WT 1M
Patients are numbered according to the pedigrees shown in Figure 1
utations are given.
The clinical evaluation is divided into following categories: FH/Gen
epol  repolarization abnormalities; Fun/Str  global and/or region
haracterization; TFC  summary of the number of major and minor diag
hether the patient fulfils major (M), minor (m), or no (0) diagnostic criN/A  data not available; WT  wild-type.entricular tachycardia (presyncope and sweating) at age 76
ears and had previously complained of palpitations. Clin-
cal sustained monomorphic ventricular tachycardia with
eft bundle branch block morphology and superior axis was
ily A with a heterozygous DSG2 G812S mutation. Black symbols indicate
myopathy (ARVC)1; white symbols indicate individuals who do not fulfill
hite symbol indicates sudden cardiac death at age 42 years. Slanted bars
plus and minus signs indicate presence or absence of DSG2 mutation,
linical evaluation. For details of the clinical evaluation, see Table 1. B:
anel A. C: Sequence electropherogram of the G¡A change at nucleotide
WT) individual (A.8). D: Sequence electropherogram of the T¡C change
al WT individual (B.2).
thy patients with novel DSG2 mutations according to the
Depol Repol Fun/Str Arr Tissue TFC
0 0 1M 1m 1M 2M  1m
0 0 0 n/a n/a 1M
0 0 1M 1m 1M 3M  1m
0 0 0 n/a n/a 1M
0 0 1M n/a n/a 2M
0 0 0 n/a n/a 0
0 0 1M n/a n/a 2M
0 0 1m n/a n/a 1M  1m
0 0 0 n/a n/a 0
0 0 0 n/a n/a 1M
1M n/a 1m 1M n/a 2M  1m
0 n/a 0 0 n/a 1M
nown symptoms are listed. The genotypes for the desmoglein-2 (DSG2)
ly history/genetics; Depol  depolarization/conduction abnormalities;
function and structural alterations; Arr  arrhythmias; Tissue  tissue
riteria for each patient (task force criteria). For each of the categories,
given.e of fam
r cardio
k and w
males;
le for c
s as in p
-type (myopa
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1449Gehmlich et al Novel Desmoglein-2 Missense Mutations in ARVCocumented. His resting ECG showed T-wave inversion in
eads V1–V3 and right bundle branch block. Echocardio-
raphy demonstrated RV dilation with small aneurysmal
reas of the free wall and moderate RV systolic dysfunction,
nondilated left ventricle with normal systolic function,
ild concentric hypertrophy, and mild left atrial dilation.
he diagnosis of ARVC was based on two major and one
inor criteria (Table 1). The patient died of cancer at age 77
ears.
Genetic screening identified a heterozygous base pair
hange in DSG2 (c.2437 T¡C change in exon 15), coding
or a cysteine to arginine substitution at amino acid 813
DSG2 C813R missense mutation; Figure 1D). No changes
ere found in the other four cardiac desmosomal genes or
x43.
There was no previous family history of cardiomyopathy
r sudden death. The only son of the index patient (indi-
idual B.2) was negative for the mutation and was clinically
ormal. No siblings of the index patient were available for
linical or genetic investigation.
mmunohistochemical changes in the presence of
DSG2 missense mutation
ndomyocardial biopsy material was available from two
ene-positive individuals of family A (Figure 2). Immuno-
istochemical analysis of both samples showed significantly
educed expression of PG at cardiac intercalated disks.
oreover, immunoreactive signal for two other desmo-
omal proteins (DSP and PKP2) was also significantly de-
ressed, whereas signal for the nondesmosomal adhesion
olecule N-cadherin was present and indistinguishable
rom controls. Furthermore, expression of the major ven-
ricular gap junction protein Cx43 was severely reduced at
ardiac intercalated disks of both affected individuals.
ased on the recently presented novel diagnostic approach,
ormal immunoreactive signal for N-cadherin and reduced
ignal for PG were consistent with previously described
olecular changes occurring in ARVC.4
ovel DSG2 missense mutations affect a
onserved region
oth novel missense mutations DSG2 G812S and DSG2
813R were absent in 400 control individuals. Further sup-
orting evidence for a pathogenic role comes from a report
f a similar mutation at amino acid position 812 of DSG2
heterozygous glycine to cysteine change: DSG2 G812C),
hich has been found to be causative for ARVC in a U.S.
atient.11
The accumulation of three ARVC mutations at two ad-
acent amino acids suggested that this region of DSG2
ight be crucial for desmosomal function. Both residues
lycine 812 and cysteine 813 are part of the completely
onserved core module in the ICS domain (Figure 3A),
hich is the domain that mediates binding of the desmo-
omal cadherins to PG.16 This implies that the three muta-
ions in this region may interfere with protein functions we.g., binding to PG) and may act via the same disease
athway.
Our binding experiments confirmed that the ICS of
SG2 links the molecule to other desmosomal components.
bacterially expressed, purified GST fusion protein frag-
ent corresponding to the DSG2 ICS bound to both PG and
KP2 from rat heart lysates (Figure 3B), whereas GST
lone showed no binding. Compared to the signal intensity
f the input control, binding to PKP2 was stronger than
inding to PG.
roperties of cytoplasmic DSG2 missense
utations
n transient transfection experiments using GFP fusion pro-
eins, all three mutant DSG2 proteins were normally incor-
orated into the intercalated disk structures of primary neo-
atal rat cardiomyocytes (Figure 4). Furthermore, none of
he three mutations affected protein stability or turnover
data not shown).
To study potential consequences of the mutations on
inding properties, the three mutations were introduced into
he GST-DSG2 ICS fusion construct and used in GST
ulldown assays. No binding differences were observed,
nd all three mutant proteins bound PG or PKP2 with an
ffinity comparable to DSG2 wild-type (Figure 3C).
We speculated that posttranslational modifications of the
SG2 ICS segment may occur in vivo, which could mod-
late binding to other desmosomal proteins, and that the
hree mutations might influence such posttranslational
odifications. Therefore, the same DSG2 ICS protein
ragments were expressed as GST fusion proteins in
ammalian COS-1 cells and probed for binding to en-
ogenous PG and PKP2 in GST pulldown assays. All
hree mutants bound to PG like the wild-type, and no
ignificant differences in the binding affinity were ob-
erved (Figure 3D). However, and in contrast to binding
xperiments with bacterially expressed protein frag-
ents, no binding to PKP2 was observed, not even for the
ild-type protein (Figure 3D).
The DSG2 C813R protein fragment migrated reproduc-
bly faster on polyacrylamide gels than did its wild-type
ounterpart (arrows in Figures 3C and 3D). To test whether
his was due to the newly introduced arginine residue in the
utant (“gain of function,” e.g., due to the additional pos-
tive charge) or the lack of the cysteine side chain, a second
utant protein was generated that contained the nonpolar
lanine residue instead of the cysteine or arginine side chain
t the same position (DSG2 C813A). The introduction of
his alanine mutation restored normal migration properties
n polyacrylamide gels (Figure 3E), suggesting that the
rginine side chain in the mutant is responsible for the
bserved electrophoretic abnormalities.
These data suggest that posttranslational modifications of
he DSG2 ICS domain may occur in mammalian cells,
hich might modulate DSG2 functions.
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RVC is a cardiac muscle disorder that is associated with
rrhythmias and heart failure of predominantly RV origin.
igure 2 Confocal immunofluorescence microscopy analysis of contro
igure 1) showing the amount of immunoreactive signal for selected juncolecular genetics postulate ARVC to be a “disease of the sesmosome.”17 However, the underlying molecular patho-
enesis and clinical characteristics, such as variable disease
xpression and incomplete penetrance, are poorly under-
ene-positive right ventricular myocardium (individuals A.1 and A.3; see
roteins at intercalated disks. Scale bars (bottom left)  10 m.l and gtood.
a(
p
p
f
s
t
c
f
c
A
e
h
f
o
c
e
c
D
N
m
p
t
m
n
d
m
C
F
A
o
o
g
a
C
c
f
d
C
1451Gehmlich et al Novel Desmoglein-2 Missense Mutations in ARVCHere we report two novel missense mutations in the ICS,
conserved region in the cytoplasmic domain of DSG2
DSG2 G812S and DSG2 C813R) identified in two ARVC
robands. The first mutation affects the same residue as the
reviously reported DSG2 G812C mutation, which was
ound in an American family,11 while the second is in the
ubsequent amino acid. Co-segregation of the missense mu-
ation DSG2 G812S with disease expression supports its
ausative role for ARVC in family A (Figure 1). The second
amily with the DSG2 C813R mutation was too small for
o-segregation analysis.
Other mutations in DSG2 have been associated with
RVC.11,18-20 Most of the mutations are located in the
xtracellular portion of the protein, but no clear correlation
as been observed between specific mutations and clinical
igure 3 Mutations in the desmoglein-2 (DSG2) intracellular cadherin
wad et al.3) The proteolytic cleavage site (scissors symbol), the five extra
f the ICS domain within the cytoplasmic portion are indicated. Sequence a
f the affected amino acids G812 and C813 (asterisks). B: Binding of
lutathione-S-transferase (GST) pulldown assays. A 1% input dilution of th
re shown (position of marker proteins is indicated on the right). Multiple
: In binding experiments similar to those shown in panel B, the binding
hanges were observed in binding of PG and PKP2. The abnormal migrati
usion proteins expressed in mammalian COS-1 cells. Binding to PG wa
etection limit. Arrow as in panel C. E: Altered electrophoretic mobility
813A mutation restores normal migration properties.eatures. Due to the small number of affected individuals in tur study and the observed variable disease expression, we
urrently cannot draw any conclusions regarding differ-
nces in phenotypes of individuals bearing extracellular or
ytoplasmic DSG2 mutations.
A few functional studies on the molecular pathology of
SG2 mutations in ARVC have been reported. A DSG2
266S transgenic mouse model, which mimics the human
utation DSG2 N271S in the extracellular domain of the
rotein, has been studied.20 This animal showed some
ypical features of ARVC, such as ventricular arrhyth-
ias and sudden cardiac death. At the histologic level,
ecrosis was observed in the transgenic hearts; however,
esmosomal structure in electron micrographs and im-
unohistochemical staining for PG, PKP2, DSP, and
x43 at the intercalated disk appeared to be normal in
nt (ICS) domain. A: Position of the mutations in DSG2. (Modified from
cadherin domains (EC), the transmembrane region (TM), and the location
nt of the ICS domain for desmosomal cadherin demonstrates conservation
lobin (PG) and plakophilin-2 (PKP2) to DSG2 ICS wild-type (WT) in
art lysate and GST-fusion protein input, together with GST alone control,
elow 50 kD in lane 1 are due to partial degradation of DSG2 ICS in vitro.
three DSG2 mutations was tested in comparison to DSG2 ICS WT. No
SG2 C813R is marked with an arrow. D: Binding experiments with GST
al for all three mutants tested, whereas binding to PKP2 was below the
2 ICS C813R in comparison to the WT protein fragment. A DSG2 ICSsegme
cellular
lignme
plakog
e rat he
bands b
of the
on of D
s norm
of DSGhis animal model.
st
s
f
D
m
m
h
p
t
c
s
r
o
c
t
t
h
a
p
C
d
t
m
l
t
m
d
c
f
c
t
a
A
a
s
i
i
c
p
o
t
t
b
l
d
c
c
w
a
c
h
c
t
m
p
s
f
i
w
i
c
e
o
p
e
F
p
b
b
1452 Heart Rhythm, Vol 7, No 10, October 2010This finding contrasts with the molecular phenotype ob-
erved in our patients with a novel mutation in the C-
erminus of DSG2. The reduction of immunoreactive signal
pecific for the desmosomal proteins DSP, PG, and PKP2
rom cardiac intercalated disks in two individuals with the
SG2 G812S mutation (Figure 2), but not in the mouse
odel, may potentially be explained by differences between
urine ARVC models and human disease. Similarly, the
eterozygous PG knockout mice reflected only certain as-
ects of human disease (arrhythmias and reduced RV func-
ion), whereas no fatty fibrotic replacement of cardiomyo-
ytes was evident in this animal model for ARVC.21
The electric isolation of cardiomyocytes by surrounding
car tissue documented in individual A.1 may promote
eentrant excitation (Online Supplement Figure 1). More-
ver, the gap junction remodeling observed in the endomyo-
ardial biopsy samples (indicated by reduced immunoreac-
ive signal for Cx43, Figure 2) may act synergistically with
he histologic abnormalities characteristic of ARVC to en-
ance conduction heterogeneity and increase the risk of
rrhythmia.7 Because loss of PKP2 was evident in the sam-
les (Figure 2), PKP2-associated conduction slowing (via
x4322 or sodium channels23) may also contribute to the
evelopment of arrhythmia.
Our functional studies on three ARVC-associated muta-
ions in the cytoplasmic domain of DSG2 suggest that these
utant proteins act in a dominant negative manner. The
ocalization and stability of the mutant proteins were iden-
ical to DSG2 wild-type (Figure 4), suggesting that the
utant proteins are likely to be incorporated into the cardiac
esmosomes of the patients. The fact that all mutations
luster in the ICS implies an important role of this domain
or DSG2 function. The affected residues are completely
onserved among desmosomal cadherins (Figure 3A), and
he ICS domain links DSG2 to the plaque proteins PKP2
igure 4 Localization of the three desmoglein-2 (DSG2) mutant proteins
roteins of DSG2 wild-type (WT) and the three mutants were transientl
eta-catenin. Nuclei were visualized with 4=,6-diamidino-2-phenylindole
ar  10 m.nd PG9 (Figure 3B). Contrary to our hypothesis (see also Fwad et al.11), none of the three mutations in the ICS
ffected binding to PG in binding assays (Figure 3C). This
uggests that the loss of PG immunoreactivity from the
ntercalated disk, as seen in our ARVC patients (Figure 2),
s a result of a more complex mechanism than just a simple
hange in binding affinity caused by the missense mutation.
In particular, posttranslational modifications may be im-
ortant in mediating the binding of DSG2 to PKP2. We
bserved striking differences in the binding properties be-
ween bacterially expressed DSG2 ICS protein and its coun-
erpart expressed in mammalian COS-1 cells. The former
ound both PG and PKP2 from rat heart lysates, whereas the
atter did not bind to PKP2, even though PKP2 is abun-
antly expressed in this cell line. Posttranslational modifi-
ations of the DSG2 ICS region may occur in mammalian
ells, which could change its affinity to PKP2. In agreement
ith this hypothesis, bacterially expressed DSG2 ICS was
ble to bind PKP2 from COS-1 cells, whereas COS-1
ell-derived DSG2 ICS did not bind to PKP2 from rat
eart extracts (Online Supplement Figure 2). In addition,
hanges in the ICS of DSG2 may affect the structure of
he adjacent regions of the cytoplasmic domain, thereby
odulating their binding properties to desmosomal com-
onents.24
Our finding that the DSG2 C813R ICS protein fragment
hows abnormal migration behavior in gel electrophoresis
urther supports a role for unknown functions beyond link-
ng DSG2 to PG and PKP2 (Figure 3E). This is only evident
hen the cysteine residue is mutated to arginine but not if it
s changed to alanine. This suggests that the observed
hange of electrophoretic properties is caused by the pres-
nce of the arginine at this position rather than by the lack
f cysteine (“gain of function”). Currently, the nature of this
henomenon is unclear. Phosphatase treatment did not alter
lectrophoretic mobility of the proteins (Online Supplement
ntercalated disk of cardiomyocytes. Green fluorescent protein (GFP) fusion
ssed in NRC. Intercalated disks were visualized by counterstaining for
. Merged images: DSG2-GFP green, beta-catenin red, DAPI blue. Scaleat the i
y expre
(DAPI)igure 3), hence an involvement of protein phosphorylation
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ite for protein palmitoylation,25 and this posttranslational
odification may modulate the functions of DSG2.26 Fi-
ally, a direct modification of this arginine at position 813
e.g. by methylation27) may occur.
Future investigations are needed to identify these addi-
ional functions of the DSG2 molecule and thereby provide
ovel insights into ARVC. This study suggests that the loss
f PG immunoreactivity at the intercalated disk is the result
f complex molecular alterations in the myocardium, which
s consistent with the fact that the immunoreactive signal for
G is reduced in the vast majority of ARVC cases, even in
hose where no mutation in a known ARVC disease gene
ould be identified.4 This observation renders the redistri-
ution of PG part of a final common pathway in ARVC
athogenesis,28 not merely stemming from disruptions in
inding affinities within the desmosomal plaque.
The elucidation of these pathologic mechanisms is the
ext step in defining pathogenesis and developing novel
herapeutic targets for patients with ARVC.
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